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Primary Care, Departments of 5Neurology, University Medical Centre, Utrecht, 6Surgery, Hospital
Amstelveen, Amstelveen, and 7Vascular Surgery, University Medical Centre, Utrecht, The NetherlandsObjective. To compare the consequences of occlusion of infrainguinal venous and prosthetic grafts.
Methods. In total, 2690 patients were included in the Dutch BOA study, a multicenter randomised trial that compared the
effectiveness of oral anticoagulants with aspirin in the prevention of infrainguinal bypass graft occlusion. Two thousand four
hundred and four patients received a femoropopliteal or femorodistal bypass with a venous (64%) or prosthetic (36%) graft.
The incidence of occlusion and amputation was calculated according to graft material and the incidence of amputation after
occlusion was compared with Cox regression to adjust for differences in prognostic factors.
Results. The indication for operation was claudication in 51%, rest pain in 20% and tissue loss in 28% of patients. The
mean follow up was 21 months.
After venous bypass grafting 171 (15%) femoropopliteal and 96 (24%) femorodistal grafts occluded. After prosthetic bypass
grafting 234 (30%) femoropopliteal and 25 (38%) femorodistal grafts occluded. Patients with occlusions in the venous group
had more severe ischemia, less runoff vessels and were older than the patients with prosthetic grafts. In the venous occlusion
group 54 (20%) amputations were performed compared to 42 (16%) in the prosthetic occlusion group; crude hazard ratio
1.17 (95% CI 0.78–1.75). After adjustment for above mentioned differences in patient characteristics the hazard ratio was
0.86 (95% CI 0.56–1.32).
Conclusion. The need for amputation after occlusion is not influenced by graft material in infrainguinal bypass surgery.Keywords: Peripheral vascular disease; Vascular surgical procedures; Vascular graft occlusion; Amputation; Femoral artery;
Popliteal artery; Tibial arteries; Intermittent claudication; Ischemia; Gangrene; Saphenous vein; Blood vessel prosthesis;
Polytetrafluoroethylene (PTFE); Polyethylene terephtalate (Dacron).Introduction
In the assessment of bypass graft surgery the main
outcome is often patency rate. An emerging focus is
functional outcome such as adequate relief of symptoms,
including relief of pain, healing of ischemic lesions,
return to unrestricted ambulation, maintenance of
independent living, and general level of patient satisfac-
tion or quality of life. Most of these parameters are
heavily influenced by a major amputation, mainly due tothe 18th annual meeting of the European Society for
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0604 + 06 $35.00/0 q 2005 Elsevier Ltd. All rights reserrestricted mobility. Only 12–13% of patients who had a
limb amputation will walk with an artificial leg.1 Five
years after a below knee amputation, 50% will be dead,
30% will have had a major contralateral amputation, and
only 20% will be alive with one intact leg.1 The rate of
amputation after bypass surgery is influenced by the
indication for operation, with a worse outcome for
critical limb ischemia (CLI) than for intermittent
claudication (IC). For CLI a more aggressive approach
in revascularisation over the years has resulted in a
decreasing amputation rate. IC is regarded only a relative
indication for surgical treatment and then only after an
adequate trial of conservative therapy.
The patency of infrainguinal saphenous vein grafts
is better than that for prosthetic grafts.2–5 However,Eur J Vasc Endovasc Surg 30, 604–609 (2005)
doi:10.1016/j.ejvs.2005.06.023, available online at http://www.sciencedirect.com onved.
Amputations After Venous and Prosthetic Bypass Occlusion 605prosthetic material may offer several advantages over
autologous grafts such as reduced operative time and
limited dissection causing lower morbidity. The
purpose of this study is to assess whether the graft
material influences the immediate and late amputation
rate after infrainguinal bypass graft occlusion.Patients and Methods
This study was part of the Dutch Bypass, Oral
anticoagulants or Aspirin (BOA) study; a multicentre,
open, randomised trial, to compare the effectiveness of
oral anticoagulants with that of aspirin in the
prevention of infrainguinal bypass-graft occlusion.
Between April 1995 and March 1998, 2690 patients
from 77 centres received an infrainguinal bypass graft
for occlusive arterial disease. A total of 40 patients
were excluded or withdrawn from the study. Demo-
graphic information, medical history, vascular risk
factors, indication for surgery, brachial and ankle
blood pressures, status of arterial outflow vessels, site
of distal anastomosis, graft material used, and
concomitant antithrombotic medication were
recorded. Randomisation was performed for treat-
ment with oral anticoagulants, with a target inter-
national normalised ratio (INR) range of 3.0–4.5, or
with 100 mg daily pulverised carbasalate calcium
(metabolised to acetylsalicylic acid, equivalent to
80 mg). The choice for autologous saphenous vein or
prosthetic grafts was left to the judgement of the
vascular surgeon. The primary outcome event was
graft occlusion, with the following secondary outcome
events: (vascular) death, myocardial infarction, stroke,
major amputation, vascular intervention, and major
haemorrhage. Follow up was performed 3 and 6
months after surgery and every 6 months thereafter,
and consisted of clinical examination with Doppler or
duplex scanning, and by arteriography if indicated.
The full study protocol and results of the Dutch BOA
study have been described previously.6
For our study purpose all patients with autologous
saphenous venous, PTFE (polytetrafluoroethylene), and
Dacron (polyethylene terephtalate) bypass grafts were
selected from the BOA database. Amputation rate after
occlusion, time interval between occlusion and amputa-
tion, and patient survival were determined.Statistics
The incidence of occlusion and amputation was
calculated according to graft material and the
incidence of amputation after occlusion was comparedwith Cox proportional hazards regression. Results are
expressed as hazard ratios, with corresponding 95%
confidence intervals. Differences in prognostic factors
between the patients with a venous or a prosthetic
graft were taken into account by the calculation of
adjusted hazard ratios. Patient survival was deter-
mined by life table analysis. Significance was deter-
mined at a P value less than .05.Results
From the total BOA population we excluded 246
patients with 169 biografts and 77 composite grafts.
The remaining 2404 patients were categorised into two
groups (Fig. 1). The venous group consisted of 1546
patients with saphenous venous grafts, of which 1140
(74%) were femoropopliteal and 406 (26%) were
femorodistal. The prosthetic group (858) consisted of
374 (44%) patients with Dacron and 484 (56%) patients
with PTFE grafts; 793 (92%) bypasses were femor-
opopliteal and 65 (8%) femorodistal. The mean
duration of follow up was 21 months for both groups.
Occlusion was verified by Doppler or duplex
scanning or angiography in 92% of patients in whom
this event occurred (Fig. 1). Table 1 shows the patient
characteristics for the two groups. Overall, the
indication for operation was claudication in 51%, rest
pain in 20% and tissue loss in 28% of patients. The
groups were similar with respect to gender and
prevalence of diabetes. However, patients with occlu-
sions in the venous group had more severe ischemia,
less runoff vessels and were older than the patients
with prosthetic grafts.
After venous bypass grafting 267 (17%) occlusions
occurred. In this occluded group 171 (15%) grafts were
femoropopliteal and 96 (24%) were femorodistal,
leading to amputations in 28 (16%) and 26 (27%)
patients, respectively. A total of 259 (30%) prosthetic
bypass grafts occluded of which 234 (30%) were
femoropopliteal and 25 (38%) were femorodistal
grafts. This resulted in an amputation in 35 (15%)
and 7 (28%) patients, respectively (Fig. 1). Thus, in the
venous occlusion group 54 (20%) amputations were
performed compared to 42 (16%) in the prosthetic
occlusion group. The crude hazard ratio was 1.17 (95%
CI 0.78–1.75) (Table 2). Fig. 2 shows the time interval
between occlusion and amputation for the two groups.
After adjustment for age, Rutherford classification and
number of runoff vessels the hazard ratio was 0.86
(95% CI 0.56–1.32). Adjustment for trial medication
had no effect on the hazard ratio estimate. Table 3
shows the amputation according to indication for
operation and graft material. When the analysis wasEur J Vasc Endovasc Surg Vol 30, 12 2005
Fig. 1. Two thousand six hundred and fifty Dutch BOA
patients and amputations after occlusions.
Table 2. Crude and adjusted hazard ratios of venous versus
prosthetic bypass material for ipsilateral amputation after graft
occlusion
Adjustments Hazard ratio 95% CI
Crude 1.17 0.78–1.75
Age 1.07 0.71–1.61
Sex 1.16 0.78–1.74
Diabetes mellitus 1.16 0.77–1.73
Rutherford classification 0.98 0.66–1.47
Runoff vessels 0.90 0.60–1.37
Site distal anastomosis 0.96 0.63–1.48
All of these but sex and
diabetes
0.86 0.56–1.32
L. Smeets et al.606restricted to patients with femoropopliteal bypasses
only, the results were essentially the same.Discussion
In this study, we found that infrainguinal bypass
graft occlusion was associated with an equal risk of
immediate and late amputation for saphenous
venous and prosthetic (Dacron and PTFE) grafts.
Off course from baseline more bypasses occluded in
the prosthetic group than in the venous group (30
versus 17%). So overall there were relatively more
occlusions and, therefore, more amputations in the
prosthetic group.Table 1. Baseline characteristics of all patients and those who develo
Graft material
Venous
All (nZ1546) Occlud
Age (years) 69G10 69G10
Male 1020 (66.0) 160 (59
Rutherford category
III 706 (45.7) 97 (36.
IV 348 (22.5) 85 (31.
V 492 (31.8) 85 (31.
Site of distal anastomosis
Femoro-popliteal 1133 (73.7) 171 (64
Femoro-distal 413 (26.3) 96 (36.
Runoff
0 62 (4.0) 14 (5.4
1 500 (32.4) 118 (44
2 510 (33.0) 69 (25.
3 475 (30.7) 66 (24.
History
Diabetes mellitus 413 (26.7) 77 (28.
Myocardial infarction 271 (17.5) 47 (17.
Allocated to trial aspirin 762 (49.3) 155 (58
Eur J Vasc Endovasc Surg Vol 30, 12 2005We used the data of the Dutch BOA study in which
patients were not randomised for graft material but for
treatment with aspirin or oral anticoagulants. Ideally,
our study question should be investigated in a
randomised controlled trial. However, the prospective
study population with 2405 patients is large and
allows for additional analysis as described in this
paper. Our results are supported by John et al. in a
prospective study on 290 above-knee femoropopliteal
bypass grafts. A total of 99 bypasses occluded with no
difference in amputation rate between saphenous vein
and PTFE after a median follow up of 20 months.7 A
more recent retrospective study by Jackson et al. of 189
femoropopliteal bypass grafts, described 57 occlu-
sions. In this study, the ischemic consequences of
femoropopliteal bypass graft occlusion were more
severe with PTFE than with saphenous vein resulting
in a higher amputation rate.8 No effect was seen of oral
anticoagulants and aspirin in terms of the amputation
rate after bypass failure.
Our findings are supported by a recent prospective
study describing 402 patients with femoropoplitealped an occlusion of their bypass
Prosthetic
ed (nZ267) All (nZ858) Occluded (nZ259)
68G10 67G10
.9) 534 (62.2) 163 (62.9)
3) 534 (62.2) 154 (59.5)
8) 141 (16.4) 44 (17.0)
8) 183 (21.4) 61 (23.5)
.0) 793 (92.4) 235 (90.3)
0) 65 (7.6) 25 (9.7)
) 19 (2.2) 8 (3.1)
.0) 191 (22.3) 66 (25.6)
9) 301 (35.1) 90 (34.5)
7) 347 (40.4) 95 (36.8)
8) 224 (26.1) 69 (26.6)
6) 152 (17.7) 46 (17.8)
.1) 446 (52.0) 125 (48.3)
Fig. 2. Time interval between occlusion and amputation with number of patients at risk.
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INR of 1.4–2.8) and aspirin or aspirin only. The
indication for surgery was limb salvage in 66% of the
patients and 100 occlusions were reported. Although
oral anticoagulants and aspirin gave less ischemia
than aspirin after PTFE graft occlusion, the incidence
of major amputation after occlusion was the same after
a median follow up of 36 months. There was no
difference between these two medication groups after
vein graft occlusion.9
A recently published randomised trial showed that
PTFE was associated with a higher incidence of
amputation after graft occlusion when compared to
Dacron.10 In our study, the rate of amputation was
similar in the patients with a Dacron (16.7%) and PTFE
(16%) graft, however, due to the low numbers of
patients and amputations in these subgroups, firm
conclusions cannot be drawn.
A total of 82 amputations were performed in 1164
patients with CLI, giving an amputation rate of 7%
over a mean follow up of 21 months. In contrast, JohnTable 3. Occlusions and amputations according to indication for ope
Graft material
Venous
All (1546) Occluded (267) Amputati
Claudication 706 97 4
Rest pain 348 85 18
Tissue loss 492 85 32et al. and Jackson et al. reported an overall amputation
rate of 22 and 18%, respectively, at 20 months. There is
general agreement that surgical revascularisation
provides durable results for critical ischemic limbs in
85–90% of cases with less mortality, shorter hospital
stay and longer survival than primary amputation.11–13
However, there is no consensus regarding the use of
operative treatment for claudicants. In a recently
presented study, the health utility outcome scores in
claudicants were similar or worse than for patients
with osteoarthritis undergoing arthroplasty.14 In spite
of a rather modest increase in walking distance these
patients experienced a substantial improvement in
quality of life (QoL) scores after intervention, which
also proved to be cost effective, at least short term. Up
to 5% of men and 2.5% of women aged 60 years or
older have symptoms of intermittent claudication.
Without revascularisation, every year about 0.3–1% of
these patients require an amputation.15,16 Only one
fourth of all claudicants deteriorate progressively
and an intervention is needed in approximatelyration and graft material
Prosthetic
on (54) All (858) Occluded (259) Amputation (42)
534 154 10
141 44 11
183 61 21
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L. Smeets et al.6080.5% per annum.17–19 Previous studies describing
femoropopliteal bypass grafting in claudicants report
an overall amputation rate of 0.5–1.4% per year.20,21 In
our study, 14 amputations were performed in a total of
1240 patients with IC giving an amputation rate of
1.1% over 21 months. Several studies report that failed
revascularisation attempts adversely affect the ulti-
mate level of amputation, resulting in more knee-joint
loss, whereas other studies report no difference.22–26 In
the event of an amputation after failure of a bypass
graft a below knee amputation is performed in about
60% and an above knee amputation in around 40%.26,27
In this study, a below, through and above knee
amputation occurred in 56, 13 and 24%, respectively.
The choice of which material to use in infrainguinal
bypass graft surgery is mostly based on the site of the
distal anastomosis, availability of adequate autolo-
gous saphenous vein, and if it is the first revascular-
isation attempt or not. There are arguments why
prosthetic grafts could be inferior to venous grafts in
the outcome after occlusion. Occlusion in prosthetic
grafts is mostly acute without a (symptomatic)
stenosis as a warning sign. This provides less time
for development of collaterals and metabolic adap-
tation of ischemic muscle. Flow in prosthetic grafts is
considered as an all-or-none situation between high
velocity flow and occlusion. Also, prosthetic grafts are
more thrombogenic than venous grafts and could
cause crural artery thromboembolism. On the other
hand, venous grafts are more susceptible to com-
pression forces compared to the (ring-enforced)
prosthetic grafts.
In spite of all these hypothetical arguments we
found no difference between venous and prosthetic
graft material in the risk of amputation after infra-
inguinal bypass occlusion.Acknowledgements
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